ArticleFrontiers in pharmacology2020
Synergistic Effects of Cryptotanshinone and Senkyunolide I in Guanxinning Tablet Against Endogenous Thrombus Formation in Zebrafish.
Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 46 citations in OpenAlex.
- Artificial Intelligence-Powered High-Content Analysis: Methodologies and Applications in Bioactive Compound Discovery from Natural Sources.Molecules (Basel, Switzerland) · 2026Review
- Integrated Liquid Chromatography-Tandem Mass Spectrometry and Headspace Solid-Phase Microextraction With Gas Chromatography-Mass Spectrometry-based Profiling Reveals Developmental Metabolic Dynamics of Ligusticum striatum DC.Journal of separation science · 2026Article
- Zebrafish as a translational platform for investigating multi-organ pharmacological interactions of traditional Chinese medicine.Frontiers in pharmacology · 2026Review
- Integrating Network Pharmacology and Metabolomics to Elucidate the Mechanism of Cryptotanshinone Against Platelet Aggregation.Current issues in molecular biology · 2025Article
- Salvianolic acid B and Senkyunolide I synergistically alleviate cardiac hypertrophy and regulate MAP3K1 signaling.Chinese medicine · 2025Article
- Discovery of active compounds in Danshen-Chuanxiong formula for blood-brain barrier protection: a multi-parametric study using an OGD/R-induced spheroid model.Journal of natural medicines · 2025Article
- Carbon dots derived from Ligusticum Chuanxiong mitigate cardiac injury by disrupting the harmful oxidative stress-apoptosis cycle.Journal of nanobiotechnology · 2025Article
- Exploring the Active Constituents ofAntioxidants (Basel, Switzerland) · 2025Article
- Evaluation of natural products bioactivity in cardiovascular diseases utilizing zebrafish models: a comprehensive review.Frontiers in pharmacology · 2025Review
- Recent Advances of the Zebrafish Model in the Discovery of Marine Bioactive Molecules.Marine drugs · 2024Review
- Brevianamide F Exerts Antithrombotic Effects by Modulating the MAPK Signaling Pathway and Coagulation Cascade.Marine drugs · 2024Article
- Guanxinning Tablet Alleviates Post-Ischemic Stroke Injury Via Regulating Complement and Coagulation Cascades Pathway and Inflammatory Network Mobilization.Drug design, development and therapy · 2024Article
- Pharmacological Mechanisms of Cryptotanshinone: Recent Advances in Cardiovascular, Cancer, and Neurological Disease Applications.Drug design, development and therapy · 2024Review
- Article
- Article
- Article
- Senkyunolide I: A Review of Its Phytochemistry, Pharmacology, Pharmacokinetics, and Drug-Likeness.Molecules (Basel, Switzerland) · 2023Review
- Quality assessment and Q-markers discovery of Tongsaimai tablet by integrating serum pharmacochemistry and network pharmacology for anti-atherosclerosis benefit.Chinese medicine · 2022Article
- Promotive effects of four herbal medicine ARCC on wound healing in mice and human.Health science reports · 2022Article
- Mechanism and Potential Target of Blood-Activating Chinese Botanical Drugs Combined With Anti-Platelet Drugs: Prevention and Treatment of Atherosclerotic Cardiovascular Diseases.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thrombosis is a key pathological event in cardiovascular diseases, and is also the most important targeting process for their clinical management. New drug development in thrombosis treatment is still in great demand. According to the traditional Chinese medicine (TCM) theory, thrombosis belongs to the syndrome of blood stasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.